International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377


International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the  Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 61

PDF Downloaded: 66

Devi, Sreedhar, Krishna, Viswa Kumar, and Naidu: Estimation of glycemic control in patients with type 2 diabetes mellites with various forms of tuberculosis with dots


Diabetes mellitus is a chronic metabolic disorder virtually affecting every organ system in the human body.1 HbA1C is regarded as the gold standard for assessing glycemic control in diabetic patients.2 Individuals with DM have three times the risk of developing TB and there are now more individuals with TB-DM co-morbidity than TB-HIV co-infection.3 Tuberculosis has been a major cause of suffering and death since times of immemorial.4 India has the largest number of TB cases estimated globally to be 2 million per annum and accounts for more than 60 million people with type 2 diabetes.5 After Introduction of Revised national tuberculosis control programme RNTCP there is significant improvements in case detection and control of TB disease, but tuberculosis is complicating diabetes.6 Another important challenge is the growing body of evidence suggesting diabetes as a risk factor for new as well as reactivated old TB cases.7 As a protocol those patients with tuberculoses having diabetes should kept on insulin to achieve glycemic control and good TB treatment outcome. But practically majority of these patients are kept on oral hypoglycemic agents (OHA) alone. This adversely affects tuberculosis treatment outcome. There is strong interaction between OHA’s and anti tuberculosis drugs leading to worsening of glycemic control.8 Poor glycemic control results in higher levels of HbA1c. On careful observation those patients kept on insulin alone with DOTS recovered fast from TB infection by showing early sputum conversion and achieved glycemic control.9 These patients showed lower level of HbA1c as compared with other two groups. This study aims at influence of glycemic control on treatment outcomes in patients with type 2 diabetes mellitus with various forms of tuberculoses.

Materials and Methods

The present study comprises patients with tuberculosis and known diabetic state registered under revised national tuberculosis control programme (RNTCP) in Dept of Pulmonology, PESIMSR, Kuppam, Chittoor district, Andhra Pradesh. Adult aged 30yrs to 80 yrs of both genders were included. Total 60 samples were tested among those 20 were OHA alone patients (Group I), 20 were OHA plus Insulin (Group II) and 20 were insulin alone (Group III) samples were analyzed at clinical Biochemistry lab PESIMSR, Kuppam. The patients with end stage complications of DM such as proliferative retinopathy and nephropathy and with history suggestive of bleeding diathesis or fits with creatinine levels ≥2 mg/dl were excluded from study. 5ml of blood was collected from the patients from the cubital vein under aseptic precautionary measures with 5ml syringe out of this 2ml was collected in EDTA tube for estimation of HbA1C. Remaining 3ml was collected in clot activator tube for blood glucose estimation. Measurement of HbA1C done by fully automatic Bio-Rad D10 - HbA1c Analyzer. Blood glucose levels were estimated by auto analyser VITROS 250.

Statistical Analysis and Results

Statistical data calculated by using SPSS software, analysis of variance (ANOVA) has been used to find the significance of study parameters between three or more groups of patient (Table 1). Post hoc test has been employed to find the pair wise significance (Table 2). A P value <0.05 was considered as significant.

Table 1

Comparison of study variables in three groups by one-way ANOVA

Study variables

Group I

Group II

Group III

p value


11.21 ± 1.08

8.92 ± 0.38

6.91 ± 0.57


Random blood glucose

321.85 ± 85.53

251.4 ± 97.05

161 ± 18.71


Table 2

Pair wise comparison in three groups by multiple comparison post-hoc test

Study variables

Group I vs Group II

Group I vs Group III

Group II vs Group III









Figure 1

HbA1c mean and SD values in three groups

Figure 2

RBS mean and SD values in three groups

The Table 1, Table 2 and Figure 1, Figure 2 shows that there was significant increased HbA1C and blood glucose levels in group I patients compared with other two groups. The mean levels of HbA1C and blood glucose in group III were 6.91 ± 0.57 and 161.2 ± 18.71 and group II the mean levels of HbA1C and blood glucose were 8.92 ± 0.471 and 215 ± 97.05. In group I the mean levels of HbA1C and blood glucose were 11.21 ± 1.08 and 321.85 ± 85.53. The level was significantly increased (p<0.001) in the group I as compared with group II and group III people.


Glycemic status should be strictly watched while diabetic patients kept on DOTS. HbA1c is considered to be a contributory factor to tissue hypoxia by increasing the affinity of hemoglobin-oxygen, while low tissue oxygen concentration is detrimental and causes oxidative stress.10 It has come to light that oxidative stress plays a crucial role in the activation and anti-TB action of isoniazid.11, 12 Rifampicin increases the hepatic metabolism of all sulphonylurea derivatives, the most widely used class of oral diabetes drugs worldwide. This effect on sulphonylurea derivatives has great inter-individual variation, which makes dose adjustments difficult and increases a patient’s risk of hyperglycaemia or hypoglycaemia. Inter-individual variation in the induction of the metabolism of diabetes drugs makes dose adjustment difficult when rifampicin treatment is interrupted or stopped; the same is true for most other oral antidiabetes drugs.13, 14 Then the oral hypoglycemic agents are rapidly eliminated. Isoniazid antagonizes the action of sulphonylureas and worsens glycemic control.15 In some situations, isoniazid decreases the metabolism of oral antiglycemic agents and increases their plasma levels, such as cytochrome P2C9 (CYP2C9) involved in the metabolism of sulphonylureas.16 That’s what oral hypoglycemic patients difficult to achieve glycemic control. Most recently, some investigators have suggested that for TB-DM patients, higher blood glucose levels contribute to the occurrence of drug resistance by delaying sputum conversion.17, 18 Glycosylated haemoglobin was very high in the patients who kept on OHA alone. Those patients kept on insulin and insulin with OHA was achieving glycemic control. The study showed improvement in insulin alone and along with OHA’s with DOTS showed improvement in glycogen control and lowered HbA1C levels as compared to OHA group patients.


The association between DM and TB is well documented and there is substantial evidence to support this fact. There is adverse interaction between anti-TB drugs and oral hypoglycemic agents. Particularly rifampcin is a potent inducer of hepatic enzyme cytocrome P450. cytocrome P450 rapidly metabolizes the oral hypoglycemic agents particularly sulfonylureas and brings the diabetic patients to uncontrolled glycemic status. Isoniazid decreases the metabolism of oral antiglycemic agents and increases their plasma levels, such as cytochrome P2C9 (CYP2C9) involved in the metabolism of sulphonylureas. Those patients kept on OHA alone there is more failure rates as compared with other two groups. TB patients kept on insulin and insulin with OHA showed better response and early sputum conversion, lowered blood glucose levels and HbA1C as compared with OHA people. Limitations of present study: small sample size.

Conflict of Interest

None declared.


Cooperation with Dept of Pulmonology, PESIMSR, Kuppam, Chittoor district, Andhra Pradesh, India.



American Diabetes Association. Diagnosis and classification of diabetes mellitusDiabetes Care200932627


ME Bryśkiewicz L Majkowska Czy hemoglobina glikowana (HbA1c) stanie sie standardem w diagnostyce cukrzycy? [Glycated hemoglobin (HbA1c) as a standard diagnostic criterium for diabetes?Pol Merkur Lekarski2011301761504


BI Restrepo Diabetes and TuberculosisMicrobiol Spectr20164610.1128/microbiolspec.tnmi7-0023-2016


K Singh PP Singh B Bhushan S Kumari V Bhagat V Bakshi Treatment outcome of pulmonary tuberculosis patients attending a tertiaryJ Med Sci Clin Res20208410.18535/jmscr/v8i4.07


TB and diabetes india- bulletin of the world health organization2011893529


RNTCP- tbc89 India history of TB control


WHO framework targets tuberculosis–diabetes link2011


BG Katjung Drug metabolismBasic and clinical pharmacology 10th edition2007


RK Kotokey DN Bhattacharya P Das AK Azad A De Study of efficacy of dots in pulmonary tuberculosis patients with associated diabetesLung India2007245860


M Samaja D Melotti A Carenini G Pozza Glycosylated haemoglobins and the oxygen affinity of whole bloodDiabetologia198223539940210.1007/BF00260950


PC Loewen PM Silva LJ Donald J Switala J Villanueva I Fita KatG-Mediated Oxidation Leading to Reduced Susceptibility of Bacteria to KanamycinACS Omega201834213910.1021/acsomega.8b00356


B Vögeli RG Rosenthal GMM Stoffel T Wagner P Kiefer NS Cortina InhA, the enoyl-thioester reductase from Mycobacterium tuberculosis forms a covalent adduct during catalysisJ Biol Chem20182934417200710.1074/jbc.ra118.005405


AL Riza F Pearson C Ugarte-Gil B Alisjahbana S Vijver NM Panduru Clinical management of concurrent diabetes and tuberculosis and the implications for patient servicesLancet Diabetes Endocrinol2014297405310.1016/s2213-8587(14)70110-x


PR Donald PD van Helden Antituberculosis Chemotherapy40201120312


HE Lebovitz H Rifkin D Porte Oral Hypoglycemic Agents. Ellenberg and Rifkins’S Diabetes Mellitus4th editionElsevierNew York, NY, USA1990


E Yorke Y Atiase J Akpalu O Sarfo-Kantanka V Boima I Dzifa Dey The Bidirectional Relationship between Tuberculosis and DiabetesTuberc Res Treat201720171702578.10.1155/2017/1702578


J Cheng H Zhang YL Zhao LX Wang MT Chen Mutual impact of diabetes mellitus and tuberculosis in ChinaBiomed Environ Sci2017303849


A Esmail NF Sabur I Okpechi K Dheda Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically illJ Thorac Dis201810531021810.21037/jtd.2018.05.11


© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Article type

Original Article

Article page


Authors Details

C Suvarna Devi, U Sreedhar, T Sharmila Krishna*, R Viswa Kumar, M Prasad Naidu

Article History

Received : 03-05-2021

Accepted : 09-06-2021

Available online : 23-07-2021

Article Metrics

View Article As


Downlaod Files


Wiki in hindi